Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Step 2: Identify your vial concentration
In the STEP 1 trial, semaglutide at 2.4 mg weekly produced nearly 15 percent average weight loss over 68 weeks
DOSING USED IN PHASE 3 STUDIES In the most recent studies from the TRIUMPH programme (Phase 3) , retatrutide was administered as follows: Route: Subcutaneous Frequency: Once weekly Study duration: Approximately 68 weeks Recommended Dosage (Clinical Research Escalation Model) Retatrutide is administered once weekly using a gradual dose escalation to improve tolerability
:max_bytes(150000):strip_icc()/VWH-GettyImages-1696998073-d9e7687b2f55477eb6cfdb5a40f1f43e.jpg)
frequency 35 days per week
US$ 29.52
US$ 27.59
US$ 26.24
US$ 24.03
US$ 27.41
US$ 29.30
US$ 22.57
US$ 20.47
